Comparing the current results to its competitors, Sanofi reported Revenue increase in the 4 quarter 2025 by 5.49 % year on year. The revenue growth was below Sanofi's competitors' average revenue growth of 11.57 %, achieved in the same quarter.
Sanofi's Comment on Competition and Industry Peers
Sanofi faces challenges to its patent protections and regulatory exclusivities for its pharmaceutical products. Despite unexpired patents, generic versions of products such as Allegra in the US and Multaq in the EU have been launched by competitors. These competitors may circumvent patents by developing different formulations, salt or crystalline forms, or indications not covered by Sanofi's patents. In the US, generic competitors can challenge patents by filing Abbreviated New Drug Applications (ANDAs) or under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act. Regulatory exclusivity periods, including the FDA's five-year exclusivity for New Chemical Entities and 12-year exclusivity for biological drugs, provide additional protection independent of patents. Sanofi is engaged in ongoing patent litigation to defend its intellectual property rights.
Alpine Immune Sciences Inc is a biotechnology company focused on developing immunotherapies to treat cancer and autoimmune diseases. Their business model involves identifying unique protein targets and using their proprietary technology platform to engineer and develop novel therapeutic antibodies that modulate the immune system. They aim to partner with pharmaceutical companies for the clinical development and commercialization of their product candidates.
Galapagos Nv's business model is centered around the development and commercialization of innovative medicines. They leverage their expertise in drug discovery and development to collaborate with partners in the healthcare industry, focusing on the advancement of novel therapies to address unmet medical needs.
Innoviva Inc's business model revolves around the development and commercialization of pharmaceutical products. The company primarily focuses on creating strategic collaborations and partnerships with biopharmaceutical companies to advance innovative therapies. Innoviva generates revenue through royalty payments received based on the sales of its partnered products.
Kiniksa Pharmaceuticals International Plc Share Performance
+105.76%
One Year
Kiniksa Pharmaceuticals International Plc
Profile
Kiniksa Pharmaceuticals Ltd is a biopharmaceutical company focused on developing and commercializing therapeutics for patients with debilitating diseases and unmet medical needs. Their business model revolves around identifying potential drug candidates, conducting rigorous research and development, and ultimately bringing these drugs to market to provide innovative treatment options. They generate revenue through the sale of their products and collaborations with other companies for the development and commercialization of their therapies.
Sources:
Sanofi’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Sanofi versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
